NYSE
0.43USD
+0.17 (+61.11%)
No scored catalysts in the window yet.
Market cap
12.8M
P/E
—
EPS
—
Beta
2.71
52W range
0.25-3.56
Day range
0.38–0.57
Open
0.41
Prev close
0.27
Volume
30.1M
Avg volume
669.9K
Dividend
0.00
IPO
2020-10-30
https://www.proactiveinvestors.co.uk/companies/news/1096712 · 8/7/2026-0.40
https://www.proactiveinvestors.co.uk/companies/news/1095109 · 7/8/2026+0.70
https://www.proactiveinvestors.co.uk/companies/news/1091148 · 4/24/2026+0.60
SQZ Biotechnologies, a biotechnology firm currently in the clinical development phase, is focused on creating cell-based therapies for various severe ailments, including cancerous growths, autoimmune disorders, and infectious diseases. Its primary experimental therapeutic, known as SQZ-PBMC-HPV, is derived from its SQZ Antigen Presenting Cells technology. This treatment is currently undergoing Phase I clinical trials, both as a standalone therapy and alongside other immune-oncology treatments, to address advanced or metastatic solid tumors positive for HPV16, encompassing cancers of the cervix, head-and-neck, anus, penis, vulva, and vagina. Furthermore, the company is progressing with SQZ-AAC-HPV, another Phase I clinical candidate targeting the same HPV16+ advanced or metastatic solid tumors, which is also being evaluated as a single agent and in conjunction with other immune-modulating agents. Beyond these, SQZ Biotechnologies is also advancing its SQZ Activating Antigen Carriers and SQZ Tolerizing Antigen Carriers platforms. Established in 2013, the company operates from its main office in Watertown, Massachusetts.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
